The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval pathway and other FDA practices. Predictions of what his tenure might achieve are scattershot.
Vinay Prasad’s FDA Appointment ‘Anything But Status Quo’ Read More »
The deal creates a 28-hospital system serving patients across New York and Connecticut.
In addition to offloading the Sound United segment for $350 million, Masimo lowered its 2025 profit forecast to account for tariffs and disclosed a cyberattack.
The abrupt end of $11 billion in public health grants nationally disrupted a program in Colorado that provides residents critical access to behavioral health and substance abuse support.
AdvaMed and its British counterpart called for urgent action to ensure the situation “does not devolve into a crisis.”
AdvaMed calls for ‘zero for zero’ medtech tariffs between US and UK Read More »
Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for vaccines and sought greater clarity: “I don’t know what they’re talking about.”
Is the New HHS Vaccine Requirement Anti-Vaccine Activism Disguised as Policy? Read More »
Although the job market did not pick up in April, layoffs were down year over year and month over month, according to BioSpace tallies. Meanwhile, Amgen, Novartis, Regeneron and Roche announced U.S. manufacturing investments that are sparking job creation.
Hiring Outlook: Biopharma Job Market Yet To Surge, but Layoffs Decline Read More »
The Massachusetts biotech will focus its efforts and resources into cemsidomide, an oral drug candidate being trialed for multiple myeloma and non-Hodgkin lymphoma.
C4 Therapeutics Shelves BRAF Blocker, Goes All-In on Multiple Myeloma Drug Read More »
En un nuevo estudio se ha demostrado que el cerebro, y en concreto ciertas neuronas hipotalámicas, es capaz de modificar la composición de la microbiota intestinal, al menos en ratones; y puede hacerlo en cuestión de horas. Este descubrimiento representa un cambio de paradigma q …
El cerebro podría modular en horas la composición de la microbiota intestinal Read More »
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the market position of Wegovy. But Eli Lilly’s Zepbound is quickly gaining ground, with sales just $300 million behind Wegovy in Q1.
Novo Vows Smoother Market Waters for Wegovy—But Analysts Are Skeptical Read More »
